NRAS Q61H

CI-VAR-00003564Explore in graph →NP_002515.1:p.Gln61HisNM_002524.4:c.183A>CClinVar 375871 CIViC 893 rs121913255

Curated evidence

Evidence by cancer (11 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–11 of 11 evidence items across 3 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Colorectal Neoplasm8
NRAS Q61H	Cetuximab	Predictive	C	Supports Resistance	—	rejected	EID3823 In a retrospective study of 368 chemotherapy-refractory metastatic colorectal cancer, patients with a NRAS mutation (n=13) treated with cetuximab in combination with standard chemotherapy were associa… (full text at CIViC) PMID 20619739 · De Roock et al., 2010 · Open in CIViC	civic
NRAS Q61H	Cetuximab + IrinotecanCombination	Predictive	C	Supports Resistance	2	accepted	EID3690 One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored NRAS Q61H was wildtype for KRAS, BRAF and PIK3CA.… (full text at CIViC) PMID 20619739 · De Roock et al., 2010 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Melanoma2
NRAS Q61H	Belvarafenib	Predictive	C	Supports Resistance	2	submitted	EID13216 A patient with melanoma harboring NRAS Q61H received belvarafenib monotherapy after two prior lines of systemic therapy and had progressive disease as the best RECIST response. The patient received be… (full text at CIViC) PMID 38470950 · Kim et al., 2024 · Open in CIViC	civic
NRAS Q61H	Ipilimumab	Predictive	B	Supports Sensitivity Response	4	submitted	EID7333 The researchers quantified ctDNA in time-intervals during the treatment of 6 patients with stage IV melanoma. The patient carrying the NRAS Q61H mutation was started on ipilimumab and responded well. … (full text at CIViC) PMID 26095797 · Tsao et al., 2015 · Open in CIViC	civic

Pleural Malignant Mesothelioma1
NRAS Q61H	(diagnostic)	Diagnostic	D	Supports Positive	3	submitted	EID7332 Mice that carried the Q61H variant had Malignant Pleural Mesothelioma and Lewis Lung Carincoma. The malignant cells where taken and each cell line was shown to readily promote lung colonization compar… (full text at CIViC) PMID 28341702 · Giannou et al., 2017 · Open in CIViC	civic